New breast cancer screening guidelines highlight mammography's limits

In May, the US Preventive Services Task Force made a significant shift in how it thinks about breast cancer screening. The task force, which sets evidence-based guidelines for preventive care, recommended that women with average breast cancer risk begin getting mammograms every two years starting at age 40, rather than waiting until 50. The reasoning seemed straightforward: breast cancer cases among women in their 40s had risen noticeably between 2015 and 2019, and Black women in particular were dying from the disease at disproportionately high rates. Carol Mangione, the task force chair, framed the change simply: start screening at 40, and it might save your life.

But the numbers tell a more complicated story. When researchers at the Lown Institute, a health care think tank, modeled what these guidelines would actually accomplish, they found something sobering. In a hypothetical group of 1,000 women, about 28 would die from breast cancer at some point in their lives if no screening happened at all. The previous guidelines, recommending mammograms starting at 50, would prevent seven of those deaths. The new guidelines, starting at 40, would prevent only two additional deaths—technically one and a half, rounded up. That means screening 1,000 women starting a decade earlier would save roughly two extra lives.

The cost of those two lives saved, however, extends far beyond the screening itself. The task force's own models project that lowering the screening age would generate an additional 62 benign biopsies and two more cases of overdiagnosis—meaning women treated for cancers that would never have harmed them. False-positive mammograms carry psychological weight that lingers for years: anxiety, sleep disruption, the persistent dread of waiting for results. Unnecessary surgeries, chemotherapy, and radiation therapies stemming from overdiagnosis cost the American health system an estimated $4 billion annually.

The tension here reflects a fundamental shift in how breast cancer behaves and how we treat it. Most breast cancers grow slowly enough that even if someone waits to seek care after noticing a lump, they still have a strong chance of survival. The median time from early detectable stages to late stages spans roughly ten years. Modern treatments—particularly anti-hormonal therapies that emerged in the 1990s—work effectively across many stages of disease. As one researcher put it, the better we get at treating a disease, the less critical early detection becomes. About one in ten breast cancers are aggressive and fast-moving enough to evade detection by mammograms done only every two years, but the majority are not.

What complicates the picture further is that these projections assume an ideal world. They presume every woman is equally attentive to her body, equally likely to seek care when she notices something wrong, and equally able to access quality medical treatment. The American reality is starkly different, particularly for Black women. Decades of residential and economic segregation have left many Black Americans uninsured or living in areas with few health care providers. Medical racism has created deep distrust of the health system itself. Black women receive lower doses of chemotherapy than white women for the same cancers. Black women are also more likely to develop triple-negative breast cancers—aggressive tumors that make up about 20 percent of all US breast cancers but occur at least twice as often in Black women, especially at younger ages. These cancers progress quickly and are harder to catch on a mammogram done every one or two years.

So the new guidelines present a paradox. For Black women who might otherwise never enter the health care system to get evaluated for breast changes, routine mammograms covered by insurance could serve as an on-ramp to earlier care and treatment. The task force's models suggest Black women might see slightly more lives saved than the general population from expanded screening. But that on-ramp leads only to the beginning of the journey. It does nothing to address the barriers that prevent Black women from getting timely treatment once a cancer is found, or the systemic inequities that drive higher mortality in the first place. A woman might get a free mammogram but then lack adequate insurance to pay for the surgery or chemotherapy that follows.

Experts argue the task force missed an opportunity by applying the same age recommendation to all women rather than tailoring guidance by race and ethnicity. Some researchers have suggested different screening ages for different groups based on risk and benefit calculations. Instead, the task force cited rising breast cancer rates among younger women across all racial and ethnic backgrounds as justification for a universal recommendation. The logic is that younger women have more years of life to gain from an early diagnosis. But that assumes the early diagnosis is what actually saved their life—a proposition that remains uncertain for many slow-growing cancers.

The deeper problem, according to health policy experts, is that expanding mammography treats a symptom rather than addressing the disease. You cannot screen your way out of health disparities. What matters is fixing the environmental, genetic, and social factors that drive higher rates of aggressive cancers in Black women, and dismantling the barriers to timely, high-quality care. Those are generational challenges that demand attention from policymakers and health institutions. In the meantime, the new guidelines will likely expose large numbers of women to unnecessary biopsies and overtreatment in pursuit of a modest mortality benefit—a trade-off that some accept and others view as a harm masquerading as prevention.